Table 2. Uni- and multivariate Proportional Hazard Cox Regression of prognostic markers for mortality.
UnadjustedHazard Ratio(95% CI) | P-value | AdjustedHazard ratio(95% CI) | P-value | |
Serum 25-OHD >30 ng/ml | Ref. Value | – | Ref. Value | – |
Serum 25-OHD 20–30 ng/ml | 0.84(0.63–1.12) | 0.234 | 0.90(0.67–1.21) | 0.48 |
Serum 25-OHD <20 ng/ml | 1.03(0.79–1.33) | 0.83 | 1.11(0.85–1.46) | 0.45 |
Age pr. Year above age 50 * | 1.04(1.03–1.06) | <0.001 | 1.05(1.03–1.06) | <0.001 |
Charlsonscore >3 | 1.53(1.11–2.11) | 0.009 | 1.49(1.06−2.09) | 0.019 |
Neutrophils ** | 1.05(1.02–1.09) | 0.004 | 1.05(1.02–1.09) | <0.001 |
Severe COPD *** | 1.48(1.13–1.93) | 0.004 | 1.41(1.06–1.86) | 0.017 |
Very Severe COPD *** | 1.97(1.45–2.67) | <0.001 | 2.19(1.58–3.02) | <0.001 |
Azithromycin Vs. Placebo | 1.03(0.84–1.27) | 0.75 | 0.97(0.78–1.20) | 0.76 |
BMI <20 | 1.18(0.91–1.53) | 0.20 | 1.30(0.99–1.70) | 0.05 |
Pack years >40 years | 1.17(0.95–1.42) | 0.14 | 1.27(1.02–1.70) | 0.034 |
Estimated hazard ratio associated with an increment of one year.
Estimated hazard ratio associated with an increment of 1 * 109 cells/L.
Moderate COPD (79–50 FEV1% predicted), Severe COPD (30–50 FEV1% predicted) [28] and Very Severe COPD (<30 FEV1% predicted).